Affiliation:
1. L. M. College of Pharmacy, India
2. Smt. B.N.B. Swaminarayan Pharmacy College, India
3. SSR College of Pharmacy, India
4. Ajman University, United Arab Emirates; Ajman University, United Arab Emirates
Abstract
Abstract Toxicological studies are essential for developing novel medications in pharmaceutical industries including ayurvedic preparation. Hence, the present study is aimed to evaluate acute and 28-days repeated dose oral toxicity of anti-obesity polyherbal granules (PHG) in Sprague Dawley rats by OECD guidelines No 425 and 407, respectively. In an acute oral toxicity study, a single dose of 2 g/kg PHG was administered to rats and mortality, body weight, and clinical observations were noted for fourteen days. However, in the subacute oral toxicity study, the PHG was administered orally at doses of 0.3, 0.5 and 1 g/kg daily for 28 days to rats. Food intake and body weight were recorded weekly. On the 29th day, rats were sacrificed and subjected to haematological, biochemical, urine, necropsy, and histopathological analysis. In an acute oral toxicity study, no treatment-related, mortality, behavioral changes, and toxicity were found throughout fourteen days. Likewise, in the sub-acute toxicity study, no mortality and toxic effects were found in haematology, biochemical, urine, necropsy and histopathological analysis in rats for 28 days of treatment with PHG. Based on these results, the LD50 of PHG was found to be greater than 2 g/kg and the no-observed-adverse-effect level (NOAEL) of PHG for rats was found to be 0.5 g/kg/day. Thus, anti-obesity polyherbal granules showed a good safety profile in animal studies and can be considered an important agent for the clinical management of obesity.
Subject
General Agricultural and Biological Sciences
Reference25 articles.
1. Non-clinical studies in the process of new drug development - part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies;ANDRADE E.L.;Brazilian Journal of Medical and Biological Research,2016
2. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control;BARRETT M.L.;Nutrition Journal,2011
3. Epidemiology of obesity and diabetes and their cardiovascular complications;BHUPATHIRAJU S.N.;Circulation Research,2016
4. Toxicity studies of Blockal, a dietary supplement containing Phase 2 Starch Neutralizer (Phase 2), a standardized extract of the common white kidney bean (Phaseolus vulgaris);CHOKSHI D.;International Journal of Toxicology,2006
5. Omega-3 supplementation in the treatment of overweight and obese children and adolescents: a systematic review;CURIONI C.C.;Journal of Functional Foods,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献